Etravirine: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Etravirine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| Line 11: | Line 11: | ||
[[Category:Non-nucleoside reverse transcriptase inhibitors]] | [[Category:Non-nucleoside reverse transcriptase inhibitors]] | ||
{{reflist}} | {{reflist|2}} | ||
[[fr:Étravirine]] | [[fr:Étravirine]] | ||
Revision as of 17:12, 4 September 2012
Etravirine (TMC-125) is an drug currently under investigation for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to entravirine. Etravirine is being developed by Tibotec, a subsidiary of Johnson & Johnson. The Food and Drug Administration is scheduled to review the safety and efficacy data for etravirine in early 2008.[1]
External links
- ↑ Stellbrink HJ. Antiviral drugs in the treatment of AIDS: what is in the pipeline? Eur J Med Res. 2007 Oct 15;12(9):483-95. PMID: 17933730